News

Basel, Switzerland, April 29, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data on drug candidates from its development pipeline were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Berlin, Germany, from April 27 to 30.

Basel, Switzerland, April 9, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved all agenda items proposed at today's Ordinary General Meeting of Shareholders for the financial year 2012. At the meeting, 59.9 percent of Basilea's share capital was represented.

Basel, Switzerland, March 7, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) released today the agenda for its April 9, 2013 Annual General Meeting (AGM).

Basel, Switzerland, February 22, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) has received a request from one of its shareholders, HBM Healthcare Investments (Cayman) Ltd., which holds more than 20% of Basilea's shares, to place the repayment of CHF 5.00 per registered share from the company's capital contribution reserve on the agenda of Basilea's upcoming ordinary general meeting of shareholders, for a total of approximately CHF 48 million.

CFO Joachim Blatter to depart company, CEO Ronald Scott to serve as interim CFO Cash position and short-term investments increased to CHF 344.0 million Target patient recruitment reached in two isavuconazole phase 3 studies with data expected in H2 2013 European regulatory review of ceftobiprole in pneumonia ongoing with first potential approval in Q4 2013 Toctino® agreement with potential U.S. filing by Stiefel early 2014 Basel, Switzerland, February 7, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) presented today full-year financial results for 2012 with an increased year-end cash position of CHF 344.0 million and a reduced net loss of CHF 53.0 million. CFO Joachim Blatter will be leaving the company to pursue other opportunities. Ronald Scott, CEO will serve as interim CFO effective February 7, 2013.

Basel, Switzerland, December 14, 2012 - Basilea Pharmaceutica Ltd. ("Basilea", SIX:BSLN) and its partner Astellas Pharma Inc. ("Astellas") announced today that patient recruitment for the isavuconazole phase 3 registration study SECURE has been completed. Isavuconazole is an investigational intravenous (i. v.) and oral broad-spectrum antifungal being jointly developed by Basilea and Astellas.

Basel, Switzerland, December 10, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has promoted Ronald Scott, previously Chief Operating Officer, to Chief Executive Officer effective January 1, 2013 to succeed Anthony Man, MD, who has decided for personal reasons to leave the company as of December 31, 2012.

Basel, Switzerland, November 22, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has initiated the next planned pharmacokinetic phase 1 healthy volunteer study in its clinical development program for BAL30072, Basilea's new investigational antibiotic with activity against multidrug-resistant Gram-negative bacteria.

Basel, Switzerland, November 6, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) reported today that new research data on its innovative anti-cancer drug BAL101553 are being presented at the 24th Symposium on "Molecular Targets and Cancer Therapeutics" taking place in Dublin, Ireland, from November 6 to 9, 2012, hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).

Basel, Switzerland, October 5, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) today reported that Basilea Pharmaceutica International Ltd. has received confirmation from European health authorities that the Marketing Authorization Application (MAA) for its novel investigational antibiotic ceftobiprole for the treatment of pneumonia in hospitals has been accepted for review under the decentralized procedure.